Moderna has announced positive mid-stage clinical trial results for its investigational combination vaccine targeting seasonal influenza and COVID-19, advancing its mRNA vaccine development strategy.

The Phase II study evaluated the company’s combined mRNA vaccine candidate designed to provide protection against both influenza viruses and SARS-CoV-2 through a single immunisation. The trial met its primary objectives by demonstrating strong immune responses against both respiratory infections among study participants.

According to the company, the immune response generated by the combination vaccine was comparable to currently approved standalone flu and COVID-19 vaccines administered separately. The study also reported an acceptable safety profile, with no unexpected safety concerns observed during the trial.

The candidate forms part of Moderna’s broader respiratory vaccine portfolio aimed at integrating multiple vaccines into a single dose to streamline vaccination programs. The company has been focusing on combination vaccines as part of its strategy to expand the commercial application of its mRNA platform beyond pandemic use cases.

The successful mid-stage trial outcome supports further clinical development of the combination vaccine, with Moderna expected to advance the candidate into later-stage studies. The program reflects ongoing pharmaceutical industry efforts to develop multi-pathogen vaccines that improve vaccination efficiency while supporting large-scale immunisation strategies.

Moderna continues to invest in combination vaccine development targeting respiratory diseases as companies explore next-generation vaccine formats aligned with evolving global vaccination requirements.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!